Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Overview of attention for article published in Journal of Clinical Oncology, June 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 7 news outlets
policy: 1 policy source
twitter: 89 X users

patent: 3 patents
f1000: 1 research highlight platform
guideline: 6 clinical guideline sources

Readers on

mendeley: 386 Mendeley

So far, Altmetric has seen 13 news stories from 7 outlets.

Patient Communication is Key to Delivering Optimal PARP Inhibitor Treatment in Ovarian Cancer

OncLive, 30 Oct 2024

Laura J Chambers, DO Honest and comprehensive patient-focused discussions during each stage of ovarian cancer treatment should…

Roche IMagyn050 Fails to Evidence Benefits of Combining Tecentriq

TrialSite News, 20 Jul 2020

Roche announced that their Phase 3 IMagyn050 clinical trial revealed that the addition of atezolizumab (Tecentriq®) to…

Should all patients with advanced ovarian cancer receive frontline maintenance therapy?

Pediatric News , 27 May 2020

The current standard frontline therapy for advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer includes…

Bevacizumab Benefit in Large-Volume Ovarian Cancer

Medscape, 08 Aug 2019

Hopes that extended antiangiogenesis exposure with bevacizumab (multiple brands) might stave off tumor growth more effectively…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 9 additional news stories.